The European Medicines Agency’s expert committee CHMP recommends expanded treatment indications for five medicines that are already approved in the EU.
These are Novo Nordisk’s Kyinsu, AstraZeneca’s pandemic influenza vaccine H5N1, Sobi’s Tryngolza and Pfizer’s Tukysa.
CHMP also recommended marketing authorisation for Eli Lilly’s Foundayo (orforglipron).